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The antigens of the Cromer blood group system are located on the
protein decay-accelerating factor (DAF). This system consists of ten
high-prevalence and three low-prevalence antigens; the molecular
basis for all of these antigens is a single nucleotide polymorphism
in the DAF gene. DAF is a 70,000-Da plasma membrane protein that
is widely distributed on all blood cells and on endothelial and
epithelial tissues. The physiological role of DAF is to inhibit the
complement cascade at the level of the critical C3 convertase step.
By this mechanism, DAF acts to protect autologous cells and tissues
from complement-mediated damage and hence can play a role in
preventing or modulating autoimmune disease and inflammation.
The use of recombinant DAF as a therapeutic agent in auto-
immunity and inflammation, and of DAF transgenic animals in
xenotransplantation, is being actively investigated. Additionally,
DAF serves as a receptor for certain strains of Escherichia coli and
certain types of enteroviruses. The DAF protein that contains the
Cromer antigens serves important roles in health and disease.
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Introduction and Historical Background
The first antigen of what would become the
Cromer blood group system was identified in 1965,
based on an antibody found in the serum of a Black
prenatal patient named Mrs. Cromer.1 Four additional
examples of antibodies to this high-prevalence antigen,
Cra, were reported in 19752 and the null phenotype,
Inab, was identified in 1982.3 A total of ten high-
prevalence antigens and three low-prevalence antigens
have now been described in the Cromer blood group
system. Since publication 3 years ago of a very
comprehensive review of the serology, biochemistry,
and molecular biology of the Cromer blood group
system in Immunohematology,4 two additional
antigens, SERF5 and ZENA,6 have been described.
Furthermore, two articles in this issue of
Immunohematology continue the work on the
Cromer blood group system, reporting the molecular
basis for a new proband with the Inab phenotype due
to a nonsense mutation7 and measuring the SERF allele
frequency at 1.1 percent in the Thai blood donor
population.8
While this work on describing and characterizing
the Cromer blood group system was proceeding,
research from an independent direction resulted in the
identification in 1969 of a substance in the plasma
membrane of the RBC that acted as an inhibitor of the
complement system.9,10 In 1981, this 70,000-Da protein
was purified and named decay-accelerating factor (DAF,
CD55) because of its ability to accelerate the decay of
the C3 convertase enzyme complex.11,12 Over the
subsequent years,extensive research has elucidated the
structural and functional features of DAF, including its
attachment to the cell membrane through a
glycosylphosphatidylinositol (GPI) anchor13,14 and the
cloning and sequencing of DAF cDNA.15,16
These two independent lines of research came
together in 1988 with the demonstration that the
Cromer blood group antigens reside on the DAF
protein.17,18 This permitted the subsequent full
molecular characterization of the Cromer blood group
system. The reader is referred to the recent review in
Immunohematology4 for the serology and molecular
biology of the Cromer blood group system. The
purpose of the current review is to describe the role
played by the DAF protein (containing the Cromer
blood group antigens) in the physiological and
pathophysiological functioning of the human body.
Complement System
Activation of complement
DAF functions in the complement system. This
system is composed of more than 30 serum and cell-
surface proteins, and it forms a major part of the innate
immune system that protects the individual from
pathogens and other foreign particles, helps to clear
immune complexes and damaged cells from the body,
and serves as a bridge to the adaptive immune
system.19,20 The complement cascade is a sequential
series of enzymatic steps that is activated by one of
three main pathways: the classical pathway begins with
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antibody-antigen complexes, which bind to and
activate C1; the alternative pathway has a constant low
level “tick-over” activation that then amplifies on
foreign surfaces; and the lectin pathway begins with
mannan-binding lectin recognition of pathogens. All
three pathways generate an enzyme complex called C3
convertase, which consists of C4b2a in the classical
and lectin pathways and C3bBb in the alternative
pathway. The C3 convertase cleaves the critical central
component of the complement cascade, C3, into the
fragments C3b and C3a. C3b itself forms part of the
alternative pathway C3 convertase, C3bBb; hence this
can also act as an amplification loop once complement
is activated by any pathway. The downstream part of
the complement cascade is a nonenzymatic
construction of the terminal complement components
C5b, C6, C7, C8, and C9 into the membrane attack
complex C5b-9. The membrane attack complex inserts
into cell membranes (of pathogens,or, if misdirected,of
autologous RBCs) and creates a pore, allowing passage
of water and ions and causing osmotic lysis of the RBC.
In addition to this dramatic end result of killing cells
through the membrane attack complex to protect the
individual from pathogens and other particles, the
complement system can protect the individual by
several other effector mechanisms. First, two key
soluble fragments of complement, C3a and C5a, are
generated from the complement cascade, and these
anaphylatoxins are potent proinflammatory molecules
that are chemotactic and activate leukocytes. Second,
the C3b itself can be covalently bound to pathogens or
immune complexes, a process of opsonization that
marks them for clearance by phagocytic cells, such as
macrophages, that have receptors for C3b or its
degradation fragments. Finally, complement forms a
connection between the innate and adaptive immune
responses, as the presence of C3d (a degradation
product of C3b) on antigen substantially lowers the
activation threshold for B cells through coligation of
the B cell receptor along with a coreceptor complex
composed of the C3d receptor (CD21) and the
signaling protein CD19.21
Inhibitors of complement activation 
Because of these destructive immune effector
pathways of complement, and because there is
continuous low-level generation of C3b through the
“tick-over” mechanism (which uses C3 bound to water
instead of C3b as part of the initial C3 convertase to
start the process), the complement system is always
poised to function against pathogens, but this leaves
self tissues at substantial risk. The safe functioning of
the complement system thus requires a robust system
of inhibitors to prevent it from damaging self tissues.
The major inhibitor targets are the C3 convertase
enzyme and the membrane attack complex. The C3
convertase enzyme can be blocked by dissociation of
its two components, C4b and C2a for the classical
pathway and C3b and Bb for the alternative pathway;
the C3 convertase decays spontaneously over time, and
inhibitory proteins that increase the decay rate are said
to have decay-accelerating activity. In addition, the C3b
or C4b component of the C3 convertase can be
cleaved by the serum protease factor I, in a reaction
that requires a cofactor and inactivates the C3
convertase; proteins that can serve as the cofactor are
said to have factor I–dependent cofactor activity. Two
serum proteins, factor H and C4-binding protein, have
both decay-accelerating activity and cofactor activity,
with factor H acting on the alternative pathway C3
convertase and C4-binding protein on the classical
pathway C3 convertase. Three membrane proteins
have regulatory activity for the C3 convertase: CR1
(CD35) is the C3b receptor and also has both decay-
accelerating activity and factor I–dependent cofactor
activity for the classical and alternative pathway C3
convertases; DAF has decay-accelerating activity for
both the classical and alternative pathway C3
convertases; and membrane cofactor protein (MCP,
CD46) has factor I–dependent cofactor activity for the
classical and alternative pathway C3 convertases. CR1
is distributed mainly on peripheral blood cells,whereas
DAF and MCP are widely distributed on peripheral
blood cells (except there is no MCP on RBCs),
endothelial cells, and epithelial cells.
There are structural and genomic links of these five
inhibitors as well as a sixth protein, the C3d receptor
(CD21), as all are composed of multiple copies of a
60–amino acid domain termed the short consensus
repeat (SCR) or the complement control protein (CCP)
module. The proteins vary in size from DAF with four
SCR domains to CR1 with 30 SCR domains. The genes
for all six of these proteins are located in a region on
the long arm of human chromosome 1 termed the
regulators of complement activation (RCA) gene
cluster.22 The existence of a gene family to control
complement activation at the C3 convertase step
highlights both the critical nature of that control point
in complement action and the importance of
protecting self tissues from complement attack. An
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additional control point for complement is at the level
of the membrane attack complex. CD59, a GPI-
anchored protein with a wide tissue distribution,
inhibits assembly of the membrane attack complex,
thus protecting RBCs from lysis.23
Structure and Function of DAF
Based on multiple biochemical and molecular
biological studies, DAF is a 70,000-Da glycoprotein
composed of four SCR domains of approximately 60
amino acids each, followed by a 67–amino acid
serine/threonine-rich region that is heavily O-
glycosylated and then a carboxyl-terminal GPI anchor
that attaches DAF to the cell membrane through direct
insertion of the phosphatidylinositol moiety into the
outer leaflet of the lipid bilayer.24 The GPI anchor is
attached during an early posttranslational modification
in which the original 28 carboxyl-terminal amino acids
of DAF protein are cleaved off and the preformed GPI
anchor is covalently attached to a serine residue at
position 319.25 Recent solution of the DAF structure
through X-ray diffraction26 shows that the four SCR
domains have a rodlike arrangement, and that the
serine/threonine-rich domain forms a rigid stalk,
holding the functional SCR domains 17.7 nm above the
plasma membrane (which is approximately 5 nm thick;
Fig. 1). The single N-linked oligosaccharide is
positioned between SCR 1 and SCR 2, and the multiple
(average 11) O-linked oligosaccharides coat the
serine/threonine-rich stalk (O-glycans attach to serine
or threonine side chains) and probably protect it from
proteolysis.
This X-ray diffraction structure of DAF, coupled
with structural data on factor B, suggests that the larger
C3 convertase complex contacts DAF in the region of
SCR 2 and SCR 3, although more precise modeling will
require the X-ray diffraction solution of the complex of
DAF with C3 convertase. Biochemical data suggest that
DAF does not bind the individual components of the
C3 convertase (such as C3b or Bb) but binds the C3bBb
or C4b2a complex, leading to dissociation of the Bb or
C2a component, respectively.27 Because DAF has a low
affinity for the isolated C3b or C4b, DAF then is
released and becomes available to inhibit another C3
convertase (Fig. 2).
On the functional level, DAF was identified and
purified by its ability to protect RBCs from
complement-mediated hemolysis.9,11 Purified DAF was
also found to have the ability to reincorporate into RBC
(and other cell) plasma membranes and protect the
cells from complement-mediated hemolysis.28 The
explanation of this ability came with the recognition
that DAF was attached to cell membranes through a
GPI anchor.13,14 This reincorporation provides a
potential route for effective delivery of DAF as a
Fig. 1. Structure of the DAF protein carrying Cromer blood group
antigens. The protein is shown in schematic form on the left, and
a structural model based on atomic coordinates derived from X-
ray diffraction data and other techniques is shown on the right
(model reproduced from Lukacik, et al.26 with permission from
National Academy of Sciences, U.S.A., copyright 2004). The
protein is composed of four SCR domains that carry out the
complement regulatory function of DAF, a 67–amino acid
serine/threonine-rich domain that is heavily O-glycosylated and
forms a stalk projecting the DAF SCR domains above the cell
surface, and a GPI anchor that inserts into the lipid bilayer of the
plasma membrane.
Fig. 2. Decay-accelerating activity of DAF for C3 convertase. (Left
panel) C3b is shown covalently attached to a cell-surface
protein, forming an alternative pathway C3 convertase by
noncovalent association with Bb. (Middle panel) DAF binds to
the C3bBb complex and dissociates Bb, destroying functional
activity of the C3 convertase. (Right panel) DAF dissociates
from the C3b, which makes it available to bind to and inhibit
another C3 convertase. The same process occurs with the
classical pathway C3 convertase, C4b2a, in which case DAF
dissociates the C2a component.
O
therapeutic agent (discussed in a later section). One
disease that highlights the function of DAF is
paroxysmal nocturnal hemoglobinuria (PNH), an
acquired hemolytic anemia in which affected
peripheral RBCs have increased sensitivity to
complement-mediated hemolysis, resulting in episodes
of hemoglobinemia and hemoglobinuria. The cause of
PNH is an acquired loss of GPI-anchored proteins in
RBCs due to a mutation in the X-linked gene PIG-A, a
gene that is required for the first step in the
biosynthesis of the GPI anchor.29 Because both DAF
and CD59 are GPI-anchored proteins, both are reduced
or absent on PNH cells and contribute to the increased
sensitivity to complement, but only lack of CD59 leads
to spontaneous intravascular hemolysis.30
Physiological Roles of DAF
Evidence from DAF knockout animals
The biochemical data on DAF demonstrated that it
inhibits complement at the level of the C3 convertase.
This was established by in vitro studies of isolated cells,
usually RBCs. But what effect does DAF have on
normal physiological function in an individual, and
how does it protect against disease?  The best evidence
to answer these questions comes from studies
comparing individuals with differing levels of DAF,with
the most direct evidence from humans with the rare
Inab phenotype (DAF-negative) and from DAF
knockout mice.31,32 In both the humans and the mice
that lack DAF, the individuals are phenotypically
normal. Neither humans nor mice lacking DAF show
increased spontaneous deposition of C3 onto RBCs.
Two important caveats must be considered in
interpreting this finding (and not concluding that DAF
is irrelevant). First, clearly, there are multiple proteins
that control complement activation, as seen in the RCA
gene family. Thus, lack of one protein could be
compensated by other proteins, some of which could
be up-regulated. Second, the set of RCA proteins differs
in mice in several ways: DAF is expressed from two
genes in the mouse, one of which encodes a GPI-
anchored DAF protein that has a broad tissue
distribution; and the other encodes a transmembrane-
anchored DAF that is expressed predominantly in the
testis.33 The two groups that produced DAF knockout
mice both targeted the GPI-anchored DAF as the
version that parallels human DAF in its structure and
expression pattern.31,32 In addition, mice, but not
humans, express a membrane protein termed Crry that
has both decay-accelerating activity and factor
I–dependent cofactor activity and is broadly expressed
in tissues. Thus, the Crry expressed on mouse RBCs
could substitute for DAF in protecting the cell from
complement deposition; in humans,RBCs express CR1,
which also has these two inhibitory functions for C3
convertase. Indeed, in vitro testing of the RBCs from
Inab phenotype individuals, or from GPI-DAF knockout
mice, using activators of the classical or alternative
pathways, demonstrates that these DAF-deficient RBCs
have increased C3b deposition although they do not
show increased hemolysis (presumably protected from
hemolysis by CD59).
Role of DAF in autoimmunity and inflammation
Because DAF protects cells from complement
attack, lack of DAF could result in damage to self
tissues, and hence be a factor in autoimmune and
inflammatory diseases. However,as already mentioned,
the Inab phenotype individuals have generally normal
health. Nonetheless, one finding that has generated
interest is that four of the seven (one probable)
identified Inab individuals have a gastrointestinal
disorder, including Crohn’s disease, a protein-losing
enteropathy, and a capillary angioma of the small
intestine.34 DAF is present on intestinal epithelium, so
it is possible that this reflects an anti-inflammatory role
of DAF, or else it could be an unrelated observation.
The small number of Inab phenotype individuals
makes it impossible to draw firm conclusions.
The recent production of DAF knockout mice by
two groups,31,32 as described earlier,has allowed a more
extensive probing of the role of DAF in autoimmune
and inflammatory disease and produced data that
support a critical role for DAF in protection of self
tissues. In an experimental model of inflammatory
bowel disease based on dextran sulfate sodium–
induced colitis, the DAF knockout mice showed
markedly worse effects both clinically (bloody
diarrhea, weight loss, and shortened colons) and
histologically (increased neutrophil and mononuclear
cell infiltration, greater epithelial cell destruction, and
increased ulcerations) compared to the wild-type
mice.35 Two studies using experimental induction of
immune complex-mediated glomerulonephritis dem-
onstrated that the DAF knockout mice experienced
more severe proteinuria, had more C3b deposition in
glomeruli and more diseased glomeruli, and had more
severe podocyte damage compared with wild-type
control mice.36,37 In a model of systemic lupus
erythematosus (MRL/lpr mice) crossed into the DAF
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knockout mice, researchers demonstrated that the DAF
knockout group had greater lymphadenopathy and
splenomegaly, higher levels of anti-chromatin
antibodies, and more severe dermatitis with increased
C3 deposition.38 Finally, a recent study of DAF
knockout mice in a model of experimental auto-
immune myasthenia gravis showed that the DAF
knockout mice had markedly reduced muscle strength
along with increased C3b deposition and increased
damage at the postsynaptic neuromuscular junction.39
Thus, evidence from multiple disease models suggests
that DAF plays an important role in protection against
tissue damage in autoimmune diseases.
Role of DAF in pregnancy
Pregnancy is maintained despite an HLA
incompatibility between mother and fetus. DAF is ex-
pressed on the placental trophoblast epithelial surface,
where it could play a role in protecting the fetus from
complement-mediated attack.40 Interestingly, a Crry
knockout mouse dies in utero with increased C3b
deposition and placental inflammation, demonstrating
the critical role that complement protection plays in
pregnancy.41 However, the Crry gene, which carries
out functions of both DAF and MCP, is not present in
humans. Both the Inab phenotype and the DAF
knockout mice are viable through pregnancy, so DAF is
not required for this purpose. But there is an unusual
consequence of DAF expression on the placenta. In
women who are immunized to Cromer antigens,
maternal plasma antibody levels decrease or disappear
during pregnancy42 and the antibody can be recovered
from the placenta,43 but not from fetal RBCs; hence
explaining the lack of HDN in Cromer antibody cases.
Additional roles of DAF
A number of other roles for DAF, some of which go
beyond a function in the complement system, have
been described. Several studies have shown that DAF
can have an antiadhesive role, blocking adhesion of
leukocytes to endothelial or epithelial surfaces44,45 and
thus modulating the inflammatory process. Cross-
linking of DAF by antibody results in signal
transduction in lymphocytes,46,47 and this supports the
possibility that ligands could initiate cell signals
through DAF. DAF has also been identified as a ligand
for CD97, a member of the seven-span transmembrane
receptor family that is rapidly up-regulated upon
leukocyte activation.48 Furthermore, both DAF and
CD97 were markedly up-regulated in brain tissue in
multiple sclerosis lesions,suggesting that they might be
involved in the inflammatory process in some way.49
However, the physiological consequences of the DAF-
CD97 interaction have not been elucidated.
DAF as a Therapeutic Agent
Given the in vivo properties of DAF in blocking the
complement cascade, one can propose the use of DAF
as an anti-inflammatory pharmaceutical agent. The key
hurdle is to deliver DAF to the target. The most direct
delivery method is to use DAF purified from a
recombinant cell line (similar to production of
recombinant factor VIII for hemophilia) and then
administer it by a parenteral route, such as intravenous
infusion. Alternatively, one could administer the
recombinant DAF locally, such as by injection into an
inflamed site. This has been tested in a guinea pig
model of immune complex–mediated inflammation, in
which intradermal injection of soluble DAF into the
skin led to a marked reduction in the size of the
inflammatory skin lesions.50 Two novel methods of
delivery of DAF have been described. DAF is attached
to the cell through a GPI anchor, and under some
circumstances DAF (and other GPI-anchored proteins)
can transfer between cells, perhaps through direct cell-
to-cell contact or through a plasma protein
intermediate. One group used this property to transfer
human DAF from RBCs to pig vascular endothelium.51
In another interesting approach,a fusion construct was
made between human DAF and a single-chain antibody
fragment that targeted a mouse RBC antigen, and this
construct successfully targeted DAF to mouse RBCs
and protected them from hemolysis by human
complement.52
A major focus of research on the therapeutic use of
DAF has been in the area of xenotransplantation.53
There is a shortage of human organs for transplan-
tation, and this has encouraged the exploration of
xenotransplantation as an option; pig organs are the
most likely source for xenotransplantation due to
anatomical and physiological similarities to human
organs. However, a major barrier to pig-to-human
transplantation is the hyperacute rejection that
destroys the transplanted organ within minutes to
hours; this is a complement-mediated process that is
activated by naturally occurring antibodies in human
and primate serum that react with pig endothelium,
rapidly causing complement deposition and destruc-
tion of the vascular endothelium. These antibodies
recognize a galactose-α1,3-galactose epitope (anti-Gal
antibodies) on pig vascular endothelium that is absent
in humans and primates.53 In an effort to block
hyperacute rejection, several groups have generated
DAF transgenic pigs and demonstrated that hyperacute
xenograft rejection can be blocked in pig-to-primate
heart, kidney, and liver transplants through use of
organs from DAF transgenic pigs.54–57 Although this is a
major achievement, substantial additional immuno-
logical barriers remain, and these xenotransplants are
destroyed by acute humoral rejection, a process that
depends on the anti-Gal antibodies but does not 
appear to be primarily dependent on complement.
Continuing research is addressing this problem
through additional immunosuppressive regimens and
the use of α1,3-galactosyltransferase knockout pigs 
that do not express the galactose-α1,3-galactose
epitope.53,58,59
DAF as a Pathogen Receptor
Perhaps because it is broadly expressed on most
cells and tissues, several viruses and bacteria have
adapted DAF as a receptor for cell adhesion, invasion,
or both. The major groups are enteroviruses and some
pathogenic Escherichia coli. The genus of entero-
viruses is in the family Picornaviridae (which includes
poliovirus and hepatitis A virus, neither of which uses
DAF as a receptor). The viruses in this family are small,
nonenveloped, positive-strand RNA viruses, and they
can cause aseptic meningitis,paralysis,myocarditis, and
pneumonia. Some of the enteroviruses that bind DAF
are echoviruses 7 and 12, enterovirus 70, coxsackie-
virus A21, and coxsackieviruses B1, B3, and B5. This
was first demonstrated for several echoviruses60,61 and
was subsequently expanded to many additional
enteroviruses.62 DAF acts as a receptor to bind the
virus to the cell,but it is not clear whether DAF by itself
leads to infection or if an additional receptor is
required. In some cases, it appears that the virus can be
endocytosed into the cell through DAF and lipid rafts,
which are microdomains of the membrane that are
enriched in cholesterol, glycosphingolipids, and GPI-
anchored proteins.63 More generally, though, the data
suggest that DAF functions to bind and concentrate the
virus on the cell membrane,where it can be transferred
to another receptor responsible for infection.64,65 Thus,
DAF serves to facilitate infection by this group of
enteroviruses, and might directly lead to infection in
some cases.
The other major group of pathogens that use DAF
as a receptor are strains of E. coli that cause urinary
tract and gastrointestinal disease. Pathogenic E. coli
must adhere to and invade mucosal surfaces to
produce infection. Many strains of E. coli contain an
adhesin, located on bacterial fimbriae, that binds to
DAF; this group of structurally related adhesins
comprises the Dr family of adhesins.66 The Dr adhesin
name derives from the fact that the specific Dr adhesin
binds to an epitope that is present in SCR 3 of DAF
from individuals of the Dr(a+) Cromer phenotype but
absent in the Dr(a–) phenotype.67 Other members of
the Dr adhesin family have different binding sites on
DAF. The binding of the Dr adhesin–positive E. coli
strains to DAF can result in internalization of the
bacteria68 and initiation of signaling pathways that can
lead to cytoskeletal rearrangements69 and cytokine
production.70,71
Summary
The recognition that the Cromer blood group
antigens reside on the DAF protein has been followed
by an explosion of information about the serological,
biochemical, and molecular biological basis of this
blood group4 and has provided molecular tools to
probe the role of Cromer (DAF) in health and disease.
DAF serves as a key regulator of the complement
system, and thus plays a role in controlling
autoimmune disease and inflammation. To protect self
tissues from damage, DAF has a broad tissue
distribution, and various bacteria and viruses have
taken advantage of this by using DAF as a receptor.
Exciting research is exploring the potential therapeutic
use of recombinant DAF in inflammation and of DAF
transgenic animals in xenotransplantation.
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